HSG 2018 poster: Enrichment strategy in early-to-moderate manifest Huntington’s disease (HD) based on CAG-Age Product (CAP) ≥400 threshold

Nov 08, 2018 by [Jeffrey D Long, Bernhard Landwehrmeyer, Giuseppe Palermo, Scott Schobel and Sarah J Tabrizi]

This poster highlights the value of applying a CAP threshold as an inclusion criterion in a hypothetical clinical trial of early-to-moderate manifest HD in order to identify a more homogeneous pattern of clinical progression on key clincial endpoints.

Current View

Receive this presentation and more content via email